Abstract
Two synthetic racemic nipecotamides, 1-decyl-3-(N,N-diethylcarbamoyl)piperidine hydrobromide ( 1) and α,α'-bis[3-(N-benzyl-N-methylcarbamoyl)piperidino]- p-xylene dihydrobromide ( 2) were resolved on a chiral α 1-acid glycoprotein semipreparative HPLC column. Thus, rac. 1 was resolved into two enantiomers 1A-(+) and 1B-(-); rac. 2 was separated into the optical antipodes 2A-(-) and 2C-(+), and the meso diastereomer 2B-(0). Also on a preparative scale, 97% pure 2C was obtained via diastereomeric salt formation using dibenzoyl-L-(-)-tartaric acid. The individual isomers were evaluated for their platelet aggregation inhibitory potency. In inhibiting ADP-induced aggregation of human platelets in vitro, 1B-(-) was 4 times more potent than its optical antipode 1A-(+), and 2C-(+) was 6 times as active as 2A-(-); the meso diastereomer 2B-(0) had intermediate activity. With collagen as the agonist, 1B-(-) was twice as active as 1A-(+), and 2C-(+), the most active compound in this series (IC 50= 0.96 μM), was 10 times more potent than its antipode 2A-(-). Again, the meso diastereomer 2B-(0) had intermediate activity. These results demonstrate the enantioselective antiplatelet actions of mono- and bis- nipecotamide derivatives.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
